RECURRENT LIP AND ORAL CAVITY SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT LIP AND ORAL CAVITY SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LIP AND ORAL CAVITY SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT LIP AND ORAL CAVITY SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails
Disease control OngoingThis study compares three different drug combinations for people with head and neck cancer that has spread or returned after immunotherapy stopped working. About 430 adults will receive either standard chemo plus cetuximab, chemo plus bevacizumab, or a combination of atezolizumab…
Matched conditions: RECURRENT LIP AND ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 07:05 UTC
-
New combo therapy aims to extend life in advanced head and neck cancer
Disease control OngoingThis study tested whether adding the drug bevacizumab to standard chemotherapy helps people with head and neck cancer that has returned or spread live longer. About 400 adults with this advanced cancer took part. The goal was to see if the combination improves overall survival co…
Matched conditions: RECURRENT LIP AND ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC